Drug Database
Back to search

Poland· PL-100427379

Dupixent

A dupilumab product containing dupilumabum, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 16 of our 19 countries.

ATC D11AH05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDupixentATCD11AH05REGISTER NO.PL-100427379PACKS LISTED7CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dupilumabumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dupilumab is registered in 16 of 19 countries.

Countries holding a registration under ATC D11AH05 (dupilumab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search dupilumab products by name

Dupilumab · ATC D11AH05

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dupilumab costs, country by country.

Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Dupilumab · price per daily dose (21.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$72.07
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Dupilumabum
Manufacturer
Sanofi Winthrop Industrie
Country
Poland (PL)
ATC code
D11AH05
ATC class
Dupilumab
Defined daily dose
21.4 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 7

  • gtin
    05909991490607
  • gtin
    05909991490614
  • gtin
    05909991490621
  • gtin
    05909991423360
  • gtin
    05909991423377
  • gtin
    05909991423384
  • gtin
    05909991423391

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

56 interactions on record for dupilumab.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dupilumab against other medicinesHow interaction checks work

Dupilumab · interactions on record

56 records

  • 27 severe
  • 22 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dupilumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dupilumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Dupixent
  • Iceland · Dupixent
  • Liechtenstein · Dupixent
  • Norway · Dupixent

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a2b01ad0-90e1-4325-bac7-c23cb4a4e359
GET /v1/drugs/a2b01ad0-90e1-4325-bac7-c23cb4a4e359?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
  "source": "urpl",
  "strength": "300 mg (150 mg/ml)",
  "packaging": "05909991423360 ¦ Rpz ¦ EU/1/17/1229/017 ¦ 134578\n1 wstrzykiwacz 2 ml\n05909991423377 ¦ Rpz ¦ EU/1/17/1229/018 ¦ 134580\n2 wstrzykiwacze 2 ml\n05909991423384 ¦ Rpz ¦ Skasowane ¦ EU/1/17/1229/019 ¦ 134583\n3 wstrzykiwacze 2 ml\n05909991423391 ¦ Rpz ¦ EU/1/17/1229/020 ¦ 134585\n6 wstrzykiwaczy 2 ml\n05909991490607 ¦ Rpz ¦ EU/1/17/1229/028 ¦ 145997\n6 wstrzykiwaczy 2 ml (opakowanie zbiorcze)\n05909991490614 ¦ Rpz ¦ EU/1/17/1229/027 ¦ 145998\n2 wstrzykiwacze 2 ml\n05909991490621 ¦ Rpz ¦ EU/1/17/1229/026 ¦ 145999\n1 wstrzykiwacz 2 ml",
  "substance": "Dupilumabum 300 mg",
  "common_name": "Dupilumabum",
  "pl_product_id": "100427379",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about dupilumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console